Tetrahydropyrido[3,4-d]pyrimidine derivatives as KRAS inhibitors

JP2025522388A5Pending Publication Date: 2026-06-16BRISTOL MYERS SQUIBB CO
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
BRISTOL MYERS SQUIBB CO
Filing Date
2023-06-08
Publication Date
2026-06-16

AI Technical Summary

Technical Problem

Current treatments for KRAS G12C mutations in cancers are ineffective due to high resistance and the lack of specific inhibitors targeting the active G12C type of KRAS protein.

Method used

Development of tetrahydropyrido[3,4-d]pyrimidine derivatives that selectively target the active KRAS G12C protein, inhibiting its function and potentially overcoming resistance.

Benefits of technology

The compounds demonstrate increased efficacy in inhibiting KRAS G12C, reducing cancer resistance and providing therapeutic benefits for cancers with KRAS G12C mutations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2023240189000001
    Figure 2023240189000001
  • Figure 2023240189000002
    Figure 2023240189000002
  • Figure 2023240189000003
    Figure 2023240189000003
Patent Text Reader

Abstract

The present disclosure provides a KRAS inhibitor. Also provided is a method of treating cancer using this compound.
Need to check novelty before this filing date? Find Prior Art